Business context and reporting period
uniQure N.V. is a gene-therapy developer; this unaudited Form 10-Q covers the three months ended March 31, 2022, with comparisons to Q1 2021. The company reported no product sales; revenue was from collaboration services. Its pipeline includes AMT-130 for Huntington’s disease and preclinical programs. CSL Behring holds exclusive global rights to the hemophilia B candidate etranacogene dezaparvovec.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / prior balance |
|---|---|---|
| Collaboration revenue | $1.8 million | $0.5 million |
| Research and development expense | $45.0 million | $32.7 million |
| Selling, general and administrative expense | $11.0 million | $12.4 million |
| Operating loss | $54.1 million | $44.5 million |
| Net loss | $46.7 million; $1.00 per share | $41.6 million; $0.91 per share |
| Cash and cash equivalents | $524.9 million | $556.3 million at Dec. 31, 2021 |
| Cash, cash equivalents and restricted cash | $528.1 million | $559.4 million at Dec. 31, 2021 |
| Net cash used in operating activities | $25.7 million | $41.3 million |
| Long-term debt | $101.4 million carrying value; $100.0 million principal | $101.0 million carrying value at Dec. 31, 2021 |
| Total liabilities | $211.1 million | $213.4 million at Dec. 31, 2021 |
Gross margin is not meaningful because the filing reports no product sales. The company had $578.2 million of current assets and $44.7 million of current liabilities at quarter-end.
Material changes versus the prior comparable period
- Revenue rose $1.3 million, mainly from $1.4 million of CSL Behring collaboration services; BMS collaboration revenue was $0.4 million, down from $0.5 million.
- R&D expense increased $12.3 million, including higher AMT-130 and preclinical/platform spending, personnel costs, and a $2.2 million fair-value expense for Corlieve contingent consideration.
- SG&A expense declined $1.4 million, chiefly because professional fees associated with the CSL licensing transaction were lower.
- Net loss widened $5.1 million. A $8.6 million net foreign-currency gain and other non-operating gains partly offset the operating loss; foreign-currency gains were $4.6 million in Q1 2021.
- Operating cash use fell $15.6 million, aided by collection of $20.0 million of CSL milestone receivables. Financing cash inflow was only $0.5 million, versus $62.6 million in Q1 2021, which included debt and ATM offering proceeds.
Outlook, management commentary, risks and unusual items
- Management estimated existing cash and cash equivalents would fund operations into the first half of 2025, conditional on achieving $175.0 million of first-commercial-sales milestones under the CSL agreement. This is an estimate, not a guarantee.
- CSL submitted global regulatory applications for etranacogene dezaparvovec in March 2022; the EMA accepted the MAA for accelerated assessment. Of $55.0 million due on the submissions, $20.0 million was received in March and the remaining $35.0 million in April 2022.
- AMT-130 U.S. Phase I/II enrollment of 26 patients was completed in March; the first two patients in the European Phase Ib/II study were dosed in February. Management expects expenses to increase as clinical and preclinical programs, staffing, manufacturing capabilities and other development activities advance.
- The Hercules facility has $100.0 million principal outstanding, with maturity in December 2025 and an interest-only period generally through December 2024. Repayment terms and cash covenants are subject to stated trial and regulatory milestones. The company reported material compliance with covenants at March 31, 2022.
- Corlieve-related contingent consideration had a $31.1 million fair value, based in part on a 55% estimated likelihood of AMT-260 entering clinical development by early 2024. Nominal commitments related to Corlieve were $223.7 million, with milestone timing and achievement uncertain.
- COVID-19 had caused longer equipment and disposable lead times, though the company said these had not materially affected development timelines as of the filing. Future disruption, clinical delays, manufacturing constraints, regulatory review, and financing availability remain risks.
- Pfizer’s three inter partes review petitions challenging two uniQure patents were instituted by the PTAB; uniQure filed its response in March 2022. The filing reports no new material legal proceedings beyond those disclosed previously.
Important facts for investors to verify
- Whether CSL’s regulatory applications progress to approval and whether subsequent commercial-sales milestones and royalties are achieved.
- AMT-130 trial safety, efficacy, enrollment and timing, including progress toward a pivotal trial.
- Cash burn and runway assumptions, especially the dependence of the stated runway on $175.0 million of CSL commercial-sales milestones.
- Debt covenant requirements, repayment timing, and the financial and development impact of Corlieve contingent obligations.
- Developments in Pfizer’s patent challenges and any manufacturing, supply-chain, COVID-related or regulatory setbacks.